DAX22.380 -2,0%Est505.501 -2,0%MSCI World4.343 -0,1%Top 10 Crypto9,1500 -0,4%Nas21.648 -2,0%Bitcoin61.028 +0,2%Euro1,1571 ±0,0%Öl112,2 +4,3%Gold4.497 -3,2%

Medincell Aktie

Kaufen

Verkaufen

Medincell Aktien-Sparplan Medincell Aktien-Sparplan

20,10 EUR -0,42 EUR -2,05 %

20.03.2026

BMN

18,56 CHF -0,17 CHF -0,91 %

20.03.2026

BRX

Medincell jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Marktkap.726,72 Mio. EUR

Div. Rendite0,00%

WKNA2N6VA

ISINFR0004065605

SymbolMDCLF

Medincell Aktien News

Sortieren:Datum Meistgelesen

12.12.24BusinesswireMedincell to Join the Euronext SBF 120 Index

09.12.24BusinesswireMedincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement

06.11.24BusinesswireMedincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3

WerbungMedincell-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

04.11.24BusinesswireMedincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241

23.09.24BusinesswireMedincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia

23.09.24BusinesswireMedincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

05.09.24BusinesswireMedincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)

03.09.24BusinesswireMedincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline

31.07.24BusinesswireMedincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress

08.05.24BusinesswireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

16.04.24BusinesswireMedincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies

08.04.24BusinesswireUnitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria

31.01.24BusinesswireMedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)

09.01.24BusinesswireMedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)

13.11.23BusinesswireMedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)

30.08.23BusinesswireMedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement

04.05.23BusinesswireMedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)

Medincell News

Medincell News: auf dieser Seite finden Sie alle Medincell News und Nachrichten zur Medincell Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Medincell News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Medincell News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.